Portfolio companies news

01 December 2015

Neothetics Tightens Guidance for Timing of Top-Line Pivotal Phase 3 Data

Neothetics, Inc., a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today tightened its guidance regarding the timing of release of top-line data for its two pivotal U.S. Phase 3 trials titled AbCONTOUR1 and AbCONTOUR2 of LIPO-202 to mid-December. LIPO-202 is the first non-invasive injectable drug candidate for reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects.

01 December 2015

Epic Sciences’ Chief Scientific Officer Named Leading Global Thinker by Foreign Policy Magazine

Epic Sciences' Chief Scientific Officer Dena Marrinucci, Ph.D., was named today by Foreign Policy magazine as one of this year’s 100 Leading Global Thinkers. Marrinucci will be honored at a gala in Washington, D.C. this evening. 

16 November 2015

Tragara and Lee's Pharma Enter into Exclusive Licensing Agreement to Develop and Commercialize TG02 in Greater China Market and South East Asia

Tragara Pharmaceuticals, Inc. (Tragara), a privately held clinical oncology company developing new treatments for cancer, announced today that China Oncology Focus Limited, an affiliate of Lee's Pharmaceutical Holdings Limited (Lee's Pharma), has licensed Tragara's oral multi-kinase inhibitor, TG02. Lee’s Pharma, a public biopharmaceutical company listed on the main board of the Hong Kong Stock Exchange (stock code: 950), has an operating history of over 20 years in China's pharmaceutical industry.

16 November 2015

First US Commercial Appointment - Atlas Genetics appoints Keith Stauffer as VP Sales & Marketing

Atlas Genetics Ltd (“Atlas Genetics” or the “Company”), the ultra-rapid ‘test and treat’ molecular diagnostics company, today announces the appointment of Keith Stauffer as VP Sales and Marketing.  Based in the newly opened Boston office, Keith will lead the launch and commercialisation of the Atlas Genetics io® System.

13 November 2015

Epic Sciences Partners with University of Pennsylvania's Abramson Cancer Center on Cancer Therapy Discoveries through Liquid Biopsy

Epic Sciences, Inc. announced today a collaboration with the Abramson Cancer Center of the University of Pennsylvania (Penn) on multiple studies to explore biomarkers, identified by analysis of circulating tumor cells (CTCs) at a single cell resolution, that are predictive of response to personalized cancer therapeutics.

12 November 2015

Clearside Biomedical, Inc. Announces Fifth Patent Issued in the U.S. Related To Proprietary Microneedle Drug Delivery Methods and Devices

Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced the U.S. Patent and Trademark Office (USPTO) granted U.S. Patent Application No. 14/523,243 as U.S. Patent No. 9,180,047 in a patent titled, "Apparatus and Methods for Ocular Injection."

12 November 2015

Neothetics Reports Third Quarter 2015 Financial Results

Neothetics, Inc.  (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today reported financial results and business progress for the third quarter 2015.

11 November 2015

Circulating tumor cells (CTCs) in patients' blood detected by Epic Sciences are an "accurate representation" of genetic aberrations found in fresh metastatic tumor samples

Most men with advanced prostate cancer, whether initially treated through surgical or chemical castration, eventually develop drug-resistant tumors. Monitoring for drug resistant genetic mutations could inform selection of the next line of therapy. Complicating this is that prostate cancer frequently metastasizes extensively in the bone, which means monitoring may require repeated and sometimes painful bone biopsies, some of which may fail to recover a tumor sample.

10 November 2015

Tobira Therapeutics Reports Third Quarter 2015 Financial Results

Tobira Therapeutics, Inc.  ( NASDAQ : TBRA), a biopharmaceutical company developing novel treatments for non-alcoholic steatohepatitis (NASH) and other serious immuno-inflammatory and fibrotic diseases, today reported business highlights and financial results for the third quarter of 2015.

10 November 2015

FDA Accepts PMA Submission for ReVision Optics’ Raindrop Near Vision Inlay

ReVision Optics, Inc. (RVO®), a leader in implantable presbyopia-correcting corneal inlay technology, announces that the U.S. Food and Drug Administration (FDA) has accepted and deemed fileable the company’s premarket approval (PMA) submission for the Raindrop® Near Vision Inlay. The Raindrop is a microscopic hydrogel inlay designed to correct presbyopia, thus reducing or eliminating the need for reading glasses. Acceptance and filing of the submission means the FDA has made a threshold determination that the Raindrop PMA submission is sufficiently complete to move forward in the FDA review and approval process.